Anteris Technologies Ltd. announces that the DurAVR? THV was used for the first time in a valve-in-valve (ViV) procedure as part of Health Canada?s Special Access Program (SAP). A ViV procedure is required for patients with a life-threatening situation wherein their current bioprosthetic aortic valve is failing due to calcification or structural deterioration, and a new heart valve must be implanted inside the failing valve.

These patients are at high risk for another surgery and require a minimally invasive treatment option. Canada?s SAP exists so that life-saving technology not currently available for commercial use in Canada can be provided when no other commercially available alternatives are suitable. Dr. Anita Asgar, Co-Director of the Structural Heart Program at the Institut de Cardiologie de Montreal (Montreal, Canada), made the request to Health Canada to use the DurAVR?

THV in a patient with a failing valve that needed optimal hemodynamic results as well as a short frame height as they were very high risk of poor hemodynamic result with a conventional ViV procedure. Dr. Asgar performed the procedure on an 84-year-old male and implanted a DurAVR? THV inside the failed surgical aortic valve replacement (SAVR).

The procedure was successful. The hemodynamic performance of the valve was outstanding in such a complex patient. The patient had an 88% reduction in mean gradient which brought the patient back to a near-normal physiologic state, with a final gradient of only 6mmHg after deploying the valve.

These results mirror what DurAVR? THV has seen in its extensive ViV bench-top studies.